Rachel L. Flynn, PhD
Associate Professor
Boston University Chobanian & Avedisian School of Medicine
Pharmacology, Physiology & Biophysics

PhD, University of Massachusetts Medical School
BS, Saint Michael's College

Pronouns: she/her/hers



In the Laboratory of Genomic stability and Cancer Therapeutics we use a combination of biochemical and cell biological approaches to study the function of mammalian telomeres. Telomeres cap the ends of linear chromosomes and provide a molecular barrier for the human genome. Following each cell division, progressive telomere shortening erodes that barrier and compromises the stability of the genome. Critically short, or dysfunctional telomeres induce replicative senescence and/or cell death and ultimately, lead to cellular aging. Cancer cells, however, overcome the replicative senescence associated with critically short telomeres by exploiting mechanisms of telomere elongation. The focus of my lab is to understand the mechanisms regulating mammalian telomere maintenance and to understand how defects in this process contribute to premature aging and cancer progression. The hope is that these studies will allow us to gain the mechanistic insight necessary to define novel targets and/or strategies in the treatment of human disease.

Associate Professor
Boston University Chobanian & Avedisian School of Medicine
Medicine
Hematology & Medical Oncology

Peter Paul Career Development Professorship
Boston University


Member
Boston University
BU-BMC Cancer Center


Co-Director
Boston University
Genome Science Institute


Graduate Faculty (Primary Mentor of Grad Students)
Boston University Chobanian & Avedisian School of Medicine, Graduate Medical Sciences




Functional characterization of the telomere repeat containIng RNA, TERRA, in telomere maintenance
03/17/2017 - 02/28/2023 (PI)
NIH/National Cancer Institute
5R01CA214880-06

Molecular Mechanisms Regulating the Alternative Lengthening of Telomeres Pathway
08/01/2016 - 02/28/2023 (PI)
NIH/National Cancer Institute
5R01CA201446-05

Defining ATR function in the Alternative Lengthening of Telomeres Pathway
10/01/2015 - 02/28/2019 (PI)
Edward Mallinckrodt, Jr. Foundation


Targeting the Alternative Lengthening of Telomeres Pathway in Cancer
10/01/2015 - 09/30/2016 (PI)
Elsa U. Pardee Foundation


Suppression of genomic instability by tuning the DNA damage response at telomeres
06/01/2013 - 05/31/2016 (PI)
NIH/National Cancer Institute
5R00CA166729-04

Probing the Alternative Lengthening (ALT) Pathway in Osteosarcoma
09/01/2013 - 03/31/2015 (PI)
Foster Foundation




Title


Yr Title Project-Sub Proj Pubs
2022 Functional characterization of the telomere repeat containing RNA, TERRA, in telomere maintenance 5R01CA214880-06
2021 Functional characterization of the telomere repeat containing RNA, TERRA, in telomere maintenance 5R01CA214880-05
2020 Functional characterization of the telomere repeat containing RNA, TERRA, in telomere maintenance 5R01CA214880-04
2020 Molecular Mechanisms Regulating the Alternative Lengthening of Telomeres Pathway 5R01CA201446-05 3
2019 Functional characterization of the telomere repeat containing RNA, TERRA, in telomere maintenance 5R01CA214880-03
2019 Molecular Mechanisms Regulating the Alternative Lengthening of Telomeres Pathway 5R01CA201446-04 3
2018 Functional characterization of the telomere repeat containing RNA, TERRA, in telomere maintenance 5R01CA214880-02
2018 Molecular Mechanisms Regulating the Alternative Lengthening of Telomeres Pathway 5R01CA201446-03 3
2017 Functional characterization of the telomere repeat containing RNA, TERRA, in telomere maintenance 1R01CA214880-01
2017 Molecular Mechanisms Regulating the Alternative Lengthening of Telomeres Pathway 5R01CA201446-02 3
Showing 10 of 15 results. Show All Results

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Mori JO, Keegan J, Flynn RL, Heaphy CM. Alternative lengthening of telomeres: mechanism and the pathogenesis of cancer. J Clin Pathol. 2024 Jan 18; 77(2):82-86.View Related Profiles. PMID: 37890990
     
  2. Zamalloa LG, Pruitt MM, Hermance NM, Gali H, Flynn RL, Manning AL. RB loss sensitizes cells to replication-associated DNA damage after PARP inhibition by trapping. Life Sci Alliance. 2023 Dec; 6(12). PMID: 37704395; PMCID: PMC10500056; DOI: 10.26508/lsa.202302067;
     
  3. Reiss M, Keegan J, Aldrich A, Lyons SM, Flynn RL. The exoribonuclease XRN2 mediates degradation of the long non-coding telomeric RNA TERRA. FEBS Lett. 2023 Jul; 597(14):1818-1836.View Related Profiles. PMID: 37191774; PMCID: PMC10524182; DOI: 10.1002/1873-3468.14639;
     
  4. Carson LM, Flynn RL. Highlighting vulnerabilities in the alternative lengthening of telomeres pathway. Curr Opin Pharmacol. 2023 Jun; 70:102380. PMID: 37149932; PMCID: PMC10247456; DOI: 10.1016/j.coph.2023.102380;
     
  5. Zamalloa LG, Pruitt MM, Hermance NM, Gali H, Flynn RL, Manning AL. RB loss sensitizes cells to replication-associated DNA damage by PARP inhibition. bioRxiv. 2023 Mar 25. PMID: 36993348; PMCID: PMC10055402; DOI: 10.1101/2023.03.25.532215;
     
  6. Floro J, Dai A, Metzger A, Mora-Martin A, Ganem NJ, Cifuentes D, Wu CS, Dalal J, Lyons SM, Labadorf A, Flynn RL. SDE2 is an essential gene required for ribosome biogenesis and the regulation of alternative splicing. Nucleic Acids Res. 2021 09 20; 49(16):9424-9443.View Related Profiles. PMID: 34365507; PMCID: PMC8450105; DOI: 10.1093/nar/gkab647;
     
  7. Mason-Osann E, Terranova K, Lupo N, Lock YJ, Carson LM, Flynn RL. RAD54 promotes alternative lengthening of telomeres by mediating branch migration. EMBO Rep. 2020 06 04; 21(6):e49495.View Related Profiles. PMID: 32337843; PMCID: PMC7271314; DOI: 10.15252/embr.201949495;
     
  8. Flynn RL, Heaphy CM. Surviving Telomere Attrition with the MiDAS Touch. Trends Genet. 2019 11; 35(11):783-785.View Related Profiles. PMID: 31526614
     
  9. Panier S, Maric M, Hewitt G, Mason-Osann E, Gali H, Dai A, Labadorf A, Guervilly JH, Ruis P, Segura-Bayona S, Belan O, Marzec P, Gaillard PHL, Flynn RL, Boulton SJ. SLX4IP Antagonizes Promiscuous BLM Activity during ALT Maintenance. Mol Cell. 2019 10 03; 76(1):27-43.e11.View Related Profiles. PMID: 31447390; PMCID: PMC6863466; DOI: 10.1016/j.molcel.2019.07.010;
     
  10. Mason-Osann E, Gali H, Flynn RL. Resolving Roadblocks to Telomere Replication. Methods Mol Biol. 2019; 1999:31-57.View Related Profiles. PMID: 31127568
     
Showing 10 of 24 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 24 publications over 15 distinct years, with a maximum of 4 publications in 2010 and 2019 and 2023

YearPublications
20051
20061
20071
20081
20104
20111
20121
20151
20161
20181
20194
20201
20211
20234
20241

2013 Foster Foundation: Award for osteosarcoma research
2012 NIH: K99/R00 Pathway to Independence Award
2012 NIH: Scholarship for Telomere Biology and DNA Repair Conference
2009 NIH: F32 Individual Fellowship (declined for ACS)
2009-2012 ACS: Individual Fellowship
2007 University of Massachusetts Medical School: Graduate School of Biomedical Science Commencement Speaker
2007-2009 NIH: T32 Training Grant by the Department of Pathology under Dr. David Louis
2003 Sigma Xi, The Scientific Research Society of NA

Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Project Mentor
Contact for Mentoring:

72 E. Concord St Silvio Conte (K)
Boston MA 02118
Google Map


Flynn's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Media Mentions
_
Co-Authors
_
Similar People
_
Same Department